Recently, the antimalarial drugs chloroquine and hydroxychloroquine have been under investigation for treatment of COVID-19 with the hypothesis that these drugs will prevent glycosylation of the angiotensin-converting-enzyme 2 (ACE2) as well as inhibit endosomal TLR activation (217, 218). This evidence concerns the gene ACE2 and COVID-19.